There are a number of specific characteristics to be considered when developing and manufacturing live bacterial vaccines.
Guido Dietrich
Advertisement
Director of bulk technologies at GlaxoSmithKline Biologicals
Articles by Guido Dietrich
Advertisement
Latest Updated Articles
Developing and Manufacturing Attenuated Live Bacterial VaccinesOctober 2nd 2008
Advertisement
Advertisement
Trending on BioPharm International
1
Regeneron's Libtayo Earns CHMP Nod for Expanded EU Dosing
2
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
3
Biomarker Testing Gaps Can Stall Targeted Oncology Therapy, BMS’s Dr Pennell Says
4
Lilly’s Omvoh Reaches 50% One-Year Remission in Pediatric Ulcerative Colitis
5